AperionDx's TBI Biomarker Kit is a revolutionary tool for the early assessment, risk stratification, and ongoing monitoring of traumatic brain injury (TBI). This blood-based panel quantifies key biomarkers including GFAP, ALDOC, NRGN, BDNF, and ST2, providing critical insights into the extent and progression of TBI.
Key Features
- Ultra-Sensitive Detection: Utilizes AperionDx's proprietary Protein-PCR technology for unparalleled sensitivity and accuracy.
- Multiplexed Biomarker Detection: Quantifies multiple biomarkers in a single well, reducing the need for multiple assays.
- Rapid Results: Delivers results in under 4 hours, enabling quick decision-making.
- Compatibility: Works with standard qPCR instruments already present in laboratories, eliminating the need for new hardware.
- High Agreement: Reports positive/negative percent agreement >97.5% vs. competing methods.
- Scalable: Available in 96- and 384-well plate formats to meet varying laboratory needs.
Benefits
- Early Assessment: Facilitates early detection and assessment of TBI, crucial for timely intervention.
- Risk Stratification: Helps in stratifying patients based on the severity of TBI, aiding in personalized treatment plans.
- Ongoing Monitoring: Enables continuous monitoring of TBI progression, supporting long-term patient management.
- Cost-Effective: Leverages existing qPCR infrastructure, reducing the need for additional investments.
- Reliable Results: Provides highly accurate and reproducible data, ensuring confidence in diagnostic outcomes.
Applications
- Research Labs: Ideal for academic and research institutions studying TBI and related conditions.
- Biotech and Pharma R&D: Supports drug development and clinical trials focused on TBI and neurological disorders.
- Clinical Labs and Hospitals: Pending regulatory approval, can be used for diagnostic and monitoring purposes in clinical settings.
How It Works
The TBI Biomarker Kit leverages AperionDx's proprietary Protein-PCR technology to detect and quantify key biomarkers associated with TBI. The process involves:
- Sample Collection: Blood samples are collected from patients suspected of having TBI.
- Assay Preparation: Samples are prepared and loaded onto standard qPCR instruments.
- Data Analysis: The kit's proprietary algorithms analyze the data to quantify the levels of GFAP, ALDOC, NRGN, BDNF, and ST2.
- Result Interpretation: Results are interpreted to assess the severity of TBI, stratify risk, and monitor progression.
Frequently Asked Questions
What biomarkers does the TBI Biomarker Kit detect?
The TBI Biomarker Kit detects GFAP, ALDOC, NRGN, BDNF, and ST2, which are key indicators of traumatic brain injury.
How long does it take to get results with the TBI Biomarker Kit?
The kit delivers results in under 4 hours, making it suitable for rapid diagnostic and monitoring needs.
Can the TBI Biomarker Kit be used with existing qPCR instruments?
Yes, the kit is designed to work with standard qPCR instruments already present in laboratories, eliminating the need for new hardware.
Is the TBI Biomarker Kit suitable for clinical use?
The kit is currently intended for research labs, biotech and pharma R&D, and drug development. Clinical use is pending regulatory approval.
What formats are available for the TBI Biomarker Kit?
The kit is available in 96- and 384-well plate formats to accommodate varying laboratory needs.
How accurate is the TBI Biomarker Kit?
The kit reports positive/negative percent agreement >97.5% vs. competing methods, ensuring high analytical sensitivity and reliability.
Next Steps
To learn more about the TBI Biomarker Kit and how it can benefit your research or clinical practice, contact our sales team. Our experts are ready to provide detailed information and answer any questions you may have.